ONCOVISTA INNOVATIVE THERAPIES, INC: 10-Q filed 2013-11-14
What ONCOVISTA INNOVATIVE THERAPIES, INC reported in its quarterly report filed 2013-11-14 (fiscal Q3 2013): 27 published measures, 74 facts as tagged in accession 0001144204-13-061962.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2013-11-14
- Fiscal period
- fiscal Q3 2013
- Accession
- 0001144204-13-061962 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ONCOVISTA INNOVATIVE THERAPIES, INC filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 160,890 | USD | |
| At 2012-12-31 | 575,266 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | -2,745,667 | USD | |
| At 2012-12-31 | -1,679,233 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 75,189 | USD | |
| At 2012-12-31 | 511,687 | USD | |
| At 2012-09-30 | 787,061 | USD | |
| At 2011-12-31 | 2,125,229 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -368,666 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -1,074,216 | USD | 273 |
| 2012-07-01 to 2012-09-30 | -368,999 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -1,278,984 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | -436,498 | USD | 273 |
| 2012-01-01 to 2012-09-30 | -1,278,425 | USD | 274 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 0 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 0 | USD | 273 |
| 2012-07-01 to 2012-09-30 | 0 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 0 | USD | 274 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | -22,982,723 | USD | |
| At 2012-12-31 | -21,908,507 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 477 | USD | |
| At 2012-12-31 | 3,464 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 4,582 | USD | 273 |
| 2012-01-01 to 2012-09-30 | 56,392 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -339,519 | USD | 92 |
| 2013-01-01 to 2013-09-30 | -1,085,588 | USD | 273 |
| 2012-07-01 to 2012-09-30 | -477,099 | USD | 92 |
| 2012-01-01 to 2012-09-30 | -1,530,193 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 160,413 | USD | |
| At 2012-12-31 | 571,802 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 0 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 152 | USD | 273 |
| 2012-07-01 to 2012-09-30 | 0 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 6,847 | USD | 274 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 2,906,557 | USD | |
| At 2012-12-31 | 2,254,499 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 1,171,313 | USD | |
| At 2012-12-31 | 933,547 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 339,519 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 1,085,588 | USD | 273 |
| 2012-07-01 to 2012-09-30 | 477,099 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 1,530,193 | USD | 274 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 222,155 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 675,690 | USD | 273 |
| 2012-07-01 to 2012-09-30 | 248,652 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 888,879 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 21,627,868 | shares | |
| At 2012-12-31 | 21,627,868 | shares |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 39,458 | USD | |
| At 2012-12-31 | 39,458 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 38,981 | USD | |
| At 2012-12-31 | 35.994 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 1,598,317 | USD | |
| At 2012-12-31 | 1,172,752 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2013-09-30 | 85,224 | USD | |
| At 2012-12-31 | 60,115 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 117,364 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 409,898 | USD | 273 |
| 2012-07-01 to 2012-09-30 | 228,447 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 641,314 | USD | 274 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 2,987 | USD | 273 |
| 2012-01-01 to 2012-09-30 | 5,235 | USD | 274 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | 0 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 0 | USD | 273 |
| 2012-07-01 to 2012-09-30 | 0 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 883 | USD | 274 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-07-01 to 2013-09-30 | -29,147 | USD | 92 |
| 2013-01-01 to 2013-09-30 | 11,372 | USD | 273 |
| 2012-07-01 to 2012-09-30 | 108,100 | USD | 92 |
| 2012-01-01 to 2012-09-30 | 251,209 | USD | 274 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 0 | USD | 273 |
| 2012-01-01 to 2012-09-30 | 0 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-01-01 to 2013-09-30 | 237,766 | USD | 273 |
| 2012-01-01 to 2012-09-30 | 60,544 | USD | 274 |
Inspect the source
- Entity
- ONCOVISTA INNOVATIVE THERAPIES, INC / CIK 0001094847
- Captured
- SEC response SHA-256
034ecc655296ec55707e21b2011e7bc05aab2b1bd1d5e47c9d631e0e4310eac5
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001094847.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))